Chugai Seiyaku Kabushiki Kaisha

Miyuki Yoshida

Nobuo Shimma

Kazuo Hattori

Jun Ohwada

Satoshi Niizuma

Hatsuo Kawada

Kenji Morikami

Nobuya Ishii

Hirosato Ebiike

Mitsuaki Nakamura

Masami Hasegawa

Takehiro Okada

Kohei Koyama

Hiroyuki Eda

Kenji Tatsuno

Shun Yamamoto

The present invention provides: a compound represented by the following formula (I): [wherein Yand Yrepresent a hydrogen atom or a halogen atom; either one of Yand Yrepresents &#x2014;NRR, and the other represents a hydrogen atom or a halogen atom; X represents an aryl group or a heteroaryl group that may be substituted; Rrepresents a hydrogen atom, or a Calkyl group that may be substituted; and Rrepresents a Calkyl group that is substituted with one or more substituents, &#x2014;COOR, &#x2014;COR, &#x2014;COSR, &#x2014;CONRR, &#x2014;NRR, or &#x2014;C&#x2550;NRR; or Rand R, together with a nitrogen atom to which they are bonded, may form a 4- to 10-membered hetero ring containing at least one nitrogen atom (wherein the hetero ring may be substituted with one or more substituents selected from Group C)], a prodrug thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical, a pharmaceutical composition, or the like, which comprises the compound.

1-(2H)-isoquinolone derivative

A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represented by formula (I): [wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and Rrepresents a cyclic substituent].

Pyrimidine derivatives as PI3K inhibitor and use thereof

Growing community of inventors

Kanagawa, Japan

Miyuki Yoshida